METHODS: The study comprised a total of thirty-three individuals diagnosed with stage I endometrioid endometrial cancer, treated with radical hysterectomy. The histological material was then examined to assess the cytoplasmic and nuclear expression of the proteins.
RESULTS: ARID1A exhibited expression in both the cytoplasm and nucleus of cancer cells, whereas BRG1 was mainly expressed in the nuclei. In addition, ARID1A exhibited a notable decrease in expression in grade 3 histology, with no significant correlation with the depth of myometrial invasion. The reduced expression was highly related to tumor expansion into the endocervix. The findings demonstrated a total absence of ARID1A expression in 27% of endometrioid carcinomas, with a significant reduction in expression in an additional 51% of cancer cells. These findings align with the most recent published data. In contrast, in the current study, BRG1 was rarely down-regulated and was extensively expressed in the majority of endometrioid carcinomas, preventing the possibility of statistical analysis.
CONCLUSIONS: In summary, ARID1A expression loss can be used as a biomarker to guide post-operative therapy; however, further investigation is needed, especially for early-stage endometrial cancer.
方法:该研究共包括33名被诊断为I期子宫内膜样癌的个体,行根治性子宫切除术。然后检查组织学材料以评估蛋白质的细胞质和核表达。
结果:ARID1A在癌细胞的细胞质和细胞核中均有表达,而BRG1主要在细胞核中表达。此外,ARID1A在3级组织学中表现出明显的表达下降,与肌层浸润深度无显著相关性。表达降低与肿瘤向子宫颈内膜的扩张高度相关。研究结果表明,在27%的子宫内膜样癌中完全不存在ARID1A表达,在另外51%的癌细胞中表达显著降低。这些发现与最新公布的数据一致。相比之下,在目前的研究中,BRG1很少下调,并且在大多数子宫内膜样癌中广泛表达,防止统计分析的可能性。
结论:总之,ARID1A表达缺失可作为指导术后治疗的生物标志物;然而,需要进一步调查,尤其是早期子宫内膜癌。